A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Keller, Jesse [1 ]
Fiala, Mark A. [1 ]
Sekhar, Jeevan [2 ]
Ceriotti, Connie [1 ]
Allen, Melissa [1 ]
Abboud, Camille N. [1 ]
Stockerl-Goldstein, Keith E. [1 ]
Wildes, Tanya M. [1 ]
Tomasson, Michael H. [1 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Reid Hosp, Richmond, IN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    DRUGS, 2012, 72 (15) : 2023 - 2032
  • [22] Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
    Baz, R.
    Walker, E.
    Karam, M. A.
    Choueiri, T. K.
    Jawde, R. A.
    Bruening, K.
    Reed, J.
    Faiman, B.
    Ellis, Y.
    Brand, C.
    Srkalovic, G.
    Andresen, S.
    Knight, R.
    Zeldis, J.
    Hussein, M. A.
    ANNALS OF ONCOLOGY, 2006, 17 (12) : 1766 - 1771
  • [23] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
    Derman, Benjamin A.
    Chari, Ajai
    Zonder, Jeffrey
    Major, Ajay
    Stefka, Andrew T.
    Jiang, Ken
    Karrison, Theodore
    Jasielec, Jagoda
    Jakubowiak, Andrzej
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
  • [24] Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)
    Falcone, Antonietta Pia
    Sanpaolo, Grazia
    Rossi, Giovanni
    Bodenizza, Carlo
    Carella, Angelo Michele
    Dell' Olio, Matte
    Greco, Michele Mario
    La Sala, Antonio
    Mantuano, Saverio
    Melillo, Lorella
    Merla, Emanuela
    Nobile, Michele
    Scalzulli, Potito R.
    Capalbo, Silvana
    Cascavilla, Nicola
    BLOOD, 2012, 120 (21)
  • [25] Carfilzomib for relapsed and refractory multiple myeloma
    Groen, K.
    van de Donk, N. W. C. J.
    Stege, C. A. M.
    Zweegman, S.
    Nijhof, I. S.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2663 - 2675
  • [26] Carfilzomib for relapsed or refractory multiple myeloma
    Tanimoto, Tetsuya
    Tsuda, Kenji
    Oshima, Kumi
    Mori, Jinichi
    Shimmura, Hiroaki
    LANCET ONCOLOGY, 2018, 19 (01): : E1 - E1
  • [27] COMBINATION OF THALIDOMIDE, PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE AND BORTEZOMIB (THADD-V) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY
    Offidani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 153 - 153
  • [28] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy L.
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2011, 118 (21) : 1705 - 1706
  • [30] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    BLOOD, 2012, 120 (21)
12345